BioCryst Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 85   

Articles published

BCRX 6.14 -0.36 (-5.54%)
price chart
BioCryst Pharmaceuticals Inc. (BCRX) Hits New 52-week Low During February 05 ...
BioCryst Pharmaceuticals Inc. (BCRX) established a new 52-week low yesterday, and could be a company to watch at the open. After opening at $6.62, BioCryst Pharmaceuticals Inc. dropped to $6.18 for a new 52-week low. By the closing bell, the company's ...
BioCryst Pharmaceuticals, Inc. (BCRX) Stock Rating Lowered by Zacks ...  Financial Market News
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Brokerage Rating Update  Investor Newswire
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)'s Insider Baker Bros. Advisors Lp ...
Because of the purchase Baker Bros. Advisors Lp made, its in the traders attention today. The insider of Biocryst Pharmaceuticals Inc, bought 207,715 shares worth $1.34 million USD. The average cost was $6.4 per share. In the last month, Baker Bros.
20.5% Stake of BioCryst Pharmaceuticals, Inc. (BCRX) Maintained by Baker ...  Financial Market News
BioCryst Pharmaceuticals, Inc. (BCRX) Cut to "Sell" at Zacks Investment Research
BioCryst Pharmaceuticals, Inc. logo Zacks Investment Research lowered shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) from a hold rating to a sell rating in a report released on Wednesday morning, ARN reports. According to Zacks, “BioCryst ...
Bros. Advisors Lp Baker Purchases 88345 Shares of BioCryst Pharmaceuticals ...  Corvus Business Newswire
Investors Tracking BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)'s  Vanguard Tribune
BioCryst Pharmaceuticals Inc. (BCRX) Hits New 52-week Low During February 02 ...
BioCryst Pharmaceuticals Inc. (BCRX) established a new 52-week low yesterday, and could be a company to watch at the open. After opening at $6.80, BioCryst Pharmaceuticals Inc. dropped to $6.44 for a new 52-week low. By the closing bell, the company's ...
BioCryst Pharmaceuticals Inc. (BCRX) Hits New 52-week Low During February 03 ...
BioCryst Pharmaceuticals Inc. (BCRX) established a new 52-week low yesterday, and could be a company to watch at the open. After opening at $6.54, BioCryst Pharmaceuticals Inc. dropped to $6.20 for a new 52-week low. By the closing bell, the company's ...
Biocryst Pharmaceuticals (BCRX) Weak On High Volume Today
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases.
Franklin Street Advisors Has $712000 Stake in BioCryst Pharmaceuticals, Inc ...  IRA Market Report
BioCryst Pharmaceuticals, Inc. (BCRX) Major Shareholder Bros. Advisors Lp ...  EMQ
Analysts Offer Predictions for BioCryst Pharmaceuticals, Inc.'s FY2016 ...
BioCryst Pharmaceuticals logo BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Research analysts at FBR & Co. dropped their FY2016 earnings estimates for shares of BioCryst Pharmaceuticals in a research report issued on Wednesday, Zacks Investment ...
Company Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Drops by -5.81%  Analyst Rating Reports
Here's Why Shares of BioCryst Pharmaceuticals, Inc. Are Falling Today
What: Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX), a biotech company that specializes in the development of small molecular drugs, sank by over 20% today on heavy volume.
BioCryst Pharmaceuticals (BCRX) Stock Drops Despite Positive Drug Trial Results  TheStreet.com
3 Biotech Stocks Are Getting Crushed: BioCryst Pharmaceuticals, Inc. (NASDAQ ...  Wall Street Point
BioCryst Pharmaceuticals, Inc. (BCRX) Major Shareholder Bros. Advisors Lp ...
BioCryst Pharmaceuticals logo BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) major shareholder Bros. Advisors Lp Baker purchased 207,715 shares of the stock in a transaction on Thursday, February 4th.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX): Quarterly Earnings Update
As per the research firms that were included in Zacks Research survey, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is projected an EPS of $-0.04 for last quarter.